Key facts
- Notable investors include Iaso Ventures, Koa Labs.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Inflection Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Inflection Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inflection Medicine
Developer of small-molecule therapeutics designed to address cancer, autoimmune, and inflammatory diseases. The company focuses on discovering and advancing kinase inhibitors and other compounds through preclinical and early clinical stages, enabling pharmaceutical partners and healthcare sectors to access novel treatment candidates aimed at unmet medical needs in oncology and immunology.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2025
- Employees
- 5
- Website
- inflectionmedicine.com/
- Ownership
- Privately Held (backing)
Inflection Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inflection Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inflection Medicine in its N-PORT filings yet. We sweep new filings monthly.